DexCom, Inc. DXCM recently announced that results from its CONNECT randomized controlled trial have been published in The New England Journal of Medicine. The study evaluated the benefits of its ...

DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced that results from the landmark CONNECT randomized controlled trial have been published in The New England Journal ...

DexCom, Inc. announced that results from the landmark CONNECT randomized controlled trial have been published in The New England Journal of Medicine (NEJM), providing rigorous evidence of the ...

Scientists tested a wearable blood sugar monitor on adults who weren't taking insulin. The results revealed a measurable ...

DexCom (DXCM) stock jumps as peer-reviewed data from a study for the G7 insulin pump in type 2 diabetes boost its Medicare coverage hopes.

A Type 2 diabetes patient prepares to attach his Dexcom sensor, part of a continuous glucose monitoring system, on his stomach at his home in Glenarden, Maryland, U.S., July 15, 2021. REUTERS/Hannah ...

The new 2026 data highlights an urgent opportunity for people with Type 2 diabetes: closing the gap between CGM's proven, transformative impact and the millions with Type 2 who lack awareness or ...